 HOUSTON, Sept. 28, 2021 GLOBE NEWSWIRE -- Salarius Pharmaceuticals, Inc. Nasdaq: SLRX, a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced the receipt of a 2.7 million payment under its existing contract with the Cancer Prevention and Research Institute of Texas CPRIT. The payment is part of a non-dilutive grant that was originally awarded in 2016 to support Salarius operations and development of its lead drug candidate, seclidemstat. Seclidemstat SP-2577 is a novel, oral tablet, reversible inhibitor of lysine-specific histone demethylase 1 LSD1, an enzyme that plays a key role in the development and progression of several cancers. 